During the American College of Rheumatology’s recent 2019 annual meeting, we caught up with Paul Emery, MD, FRCP, MA, FMedSci. Emery is the Versus Arthritis Professor of Rheumatology, University of Leeds, and the Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust in the United Kingdom. In this episode of the podcast, we’re sharing highlights of our interview with Emery about biosimilars.
During the American College of Rheumatology’s recent 2019 annual meeting, we caught up with Paul Emery, MD, FRCP, MA, FMedSci. Emery is the Versus Arthritis Professor of Rheumatology, University of Leeds, and the Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust in the United Kingdom. In this episode of the podcast, we’re sharing highlights of our interview with Emery about biosimilars.
Read more about the pooled analysis and the COMET study.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.